Nov.02 -- China’s drug makers are racing to leapfrog other pharma firms in developing a coronavirus vaccine. But that speed is raising questions about how stringently they’re vetting and reporting potential safety issues. Bloomberg’s Emma O’Brien reports on “Bloomberg Daybreak: Asia.”